founder & Executive Officer
SJ (Sung Joo) LEE, Ph.D.
Sung Joo Lee is the chief executive officer and founder of Orum Therapeutics. He has initiated and led many research and drug discovery efforts, uniting diverse internal and external scientific teams.
Before founding Orum in 2016, Sung Joo spent five years at LG Life Sciences and then more than six years at Sanofi; first as the Korea R&D leader and then as head of research for Asia Pacific R&D. In the latter role, he initiated and led projects around a virtual biotech model to co-invent drugs with biotech and academia teams based in Korea, China, and Japan. He also oversaw collaborations with various partners in the region, including the Institute Pasteur, Asan Medical Center, and KAIST.
Throughout his career, Sung Joo has worked to improve the therapeutic landscape for various diseases, including hepatitis B, hepatocellular carcinoma (HCC), diabetes, and Alzheimer’s disease.
Sung Joo earned a Ph.D. in biophysics from the University of California, Berkeley.
Yong-Sung KIM, Ph.D.
Yong-Sung Kim is a scientific co-founder of Orum Therapeutics and a pioneer in antibody engineering for therapeutic applications. He has published more than 95 peer-reviewed articles and holds multiple domestic and international patents. To date, Yong-Sung has transferred four antibody-related technologies to companies in Korea and the United States.
For the last 14 years, Yong-Sung has worked as an associate professor in the department of molecular science and technology at Ajou University (Suwon, Korea), which included a one-year sabbatical at Genentech Inc. in San Francisco, USA. His academic work has focused on the development of platform technology for next generation therapeutic antibodies, including cellular cytosol-penetrating antibodies and heterodimeric Fc-based bispecific antibodies. His group also deploys using yeast surface display technology for advanced antibody and protein engineering.
Yong-Sung obtained a master’s degree in biotechnology from KAIST (Daejeon, Korea) and a Ph.D. in pharmaceutical sciences from the University of Colorado in the United States. This was followed by a post-doctoral position in the laboratory of Professor K. Dane Wittrup at MIT (Cambridge, USA).